Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Michael Bristow to Treatment Outcome

This is a "connection" page, showing publications Michael Bristow has written about Treatment Outcome.

 
Connection Strength
  
 
 
1.152
  
  1. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail. 2007 Nov; 13(9):769-73.
    View in: PubMed
    Score: 0.104
  2. Altman NL, Gill EA, Kahwash R, Meyer LK, Wagner JA, Karimpour-Fard A, Berning AA, Minobe WA, Carroll IA, Jonas ER, Slavov D, Emani S, Abraham WT, Gollah AR, Ellis SL, Taylor MRG, Graw SL, Mestroni L, McKinsey TA, Buttrick PM, Kao DP, Bristow MR. Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy. Circ Heart Fail. 2025 Apr; 18(4):e012484.
    View in: PubMed
    Score: 0.087
  3. Doran B, Mei C, Varosy PD, Kao DP, Saxon LA, Feldman AM, DeMets D, Bristow MR. The Addition of a Defibrillator to?Resynchronization Therapy Decreases?Mortality in Patients With Nonischemic Cardiomyopathy. JACC Heart Fail. 2021 06; 9(6):439-449.
    View in: PubMed
    Score: 0.067
  4. Shamoun F, De Marco T, DeMets D, Mei C, Lindenfeld J, Saxon LA, Boehmer JP, Leigh J, Yong P, Feldman AM, Bristow MR. Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization Therapy. JACC Heart Fail. 2019 04; 7(4):281-290.
    View in: PubMed
    Score: 0.057
  5. Piccini JP, Connolly SJ, Abraham WT, Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Veldhuisen DJ, Sauer WH, White M, Wilton SB, Anand IS, Dufton C, Marshall DA, Aleong RG, Davis GW, Clark RL, Emery LL, Bristow MR. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. Am Heart J. 2018 05; 199:51-58.
    View in: PubMed
    Score: 0.053
  6. Bristow MR, Saxon LA, Feldman AM, Mei C, Anderson SA, DeMets DL. Lessons Learned and Insights Gained in?the?Design, Analysis, and Outcomes of?the COMPANION Trial. JACC Heart Fail. 2016 07; 4(7):521-535.
    View in: PubMed
    Score: 0.047
  7. Taylor MR, Sun AY, Davis G, Fiuzat M, Liggett SB, Bristow MR. Race, common genetic variation, and therapeutic response disparities in heart failure. JACC Heart Fail. 2014 Dec; 2(6):561-72.
    View in: PubMed
    Score: 0.042
  8. Fiuzat M, O'Connor CM, Gueyffier F, Mascette AM, Geller NL, Mebazaa A, Voors AA, Adams KF, Pi?a IL, Neyses L, Muntendam P, Felker GM, Pitt B, Zannad F, Bristow MR. Biomarker-guided therapies in heart failure: a forum for unified strategies. J Card Fail. 2013 Aug; 19(8):592-9.
    View in: PubMed
    Score: 0.039
  9. Aleong RG, Sauer WH, Davis G, Murphy GA, Port JD, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, Bristow MR. Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013 Aug; 1(4):338-344.
    View in: PubMed
    Score: 0.039
  10. Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013 Feb; 6(1):137-43.
    View in: PubMed
    Score: 0.037
  11. Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar; 15(3):324-33.
    View in: PubMed
    Score: 0.037
  12. Bristow MR. Treatment of chronic heart failure with ?-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011 Oct 28; 109(10):1176-94.
    View in: PubMed
    Score: 0.034
  13. O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, Gattis-Stough W, Davis GW, Bristow MR. Influence of global region on outcomes in heart failure ?-blocker trials. J Am Coll Cardiol. 2011 Aug 23; 58(9):915-22.
    View in: PubMed
    Score: 0.034
  14. Sumner AD, Boehmer JP, Saxon LA, Carson P, Feldman AM, Galle E, Bristow MR. Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy. Congest Heart Fail. 2009 Jul-Aug; 15(4):159-64.
    View in: PubMed
    Score: 0.029
  15. Saxon LA, Olshansky B, Volosin K, Steinberg JS, Lee BK, Tomassoni G, Guarnieri T, Rao A, Yong P, Galle E, Leigh J, Ecklund F, Bristow MR. Influence of left ventricular lead location on outcomes in the COMPANION study. J Cardiovasc Electrophysiol. 2009 Jul; 20(7):764-8.
    View in: PubMed
    Score: 0.029
  16. Movsesian M, Stehlik J, Vandeput F, Bristow MR. Phosphodiesterase inhibition in heart failure. Heart Fail Rev. 2009 Dec; 14(4):255-63.
    View in: PubMed
    Score: 0.028
  17. De Marco T, Wolfel E, Feldman AM, Lowes B, Higginbotham MB, Ghali JK, Wagoner L, Kirlin PC, Kennett JD, Goel S, Saxon LA, Boehmer JP, Mann D, Galle E, Ecklund F, Yong P, Bristow MR. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail. 2008 Feb; 14(1):9-18.
    View in: PubMed
    Score: 0.027
  18. Sauer WH, Bristow MR. The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial in perspective. J Interv Card Electrophysiol. 2008 Jan; 21(1):3-11.
    View in: PubMed
    Score: 0.026
  19. Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR. Rationale and design of the enoximone clinical trials program. J Card Fail. 2005 Dec; 11(9):659-69.
    View in: PubMed
    Score: 0.023
  20. Rivera DA, Bristow MR. Cardiac resynchronization--a heart failure perspective. Ann Noninvasive Electrocardiol. 2005 Oct; 10(4 Suppl):16-23.
    View in: PubMed
    Score: 0.023
  21. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004 Sep 14; 110(11):1437-42.
    View in: PubMed
    Score: 0.021
  22. Cleland JGF, Bristow MR, Freemantle N, Olshansky B, Gras D, Saxon L, Tavazzi L, Boehmer J, Ghio S, Feldman AM, Daubert JC, de Mets D. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF. Eur J Heart Fail. 2022 06; 24(6):1080-1090.
    View in: PubMed
    Score: 0.018
  23. Thornton CS, Huntley K, Berenger BM, Bristow M, Evans DH, Fonseca K, Franko A, Gillrie MR, Lin YC, Povitz M, Shafey M, Conly JM, Tremblay A. Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob Resist Infect Control. 2022 02 05; 11(1):28.
    View in: PubMed
    Score: 0.018
  24. Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Am Heart J. 2022 04; 246:136-143.
    View in: PubMed
    Score: 0.017
  25. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
    View in: PubMed
    Score: 0.017
  26. Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail. 2001 Jun; 7(2 Suppl 1):8-12.
    View in: PubMed
    Score: 0.017
  27. Bristow MR, Zisman LS, Lowes BD, Abraham WT, Badesch DB, Groves BM, Voelkel NF, Lynch DM, Quaife RA. The pressure-overloaded right ventricle in pulmonary hypertension. Chest. 1998 Jul; 114(1 Suppl):101S-106S.
    View in: PubMed
    Score: 0.014
  28. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998 May; 31(6):1336-40.
    View in: PubMed
    Score: 0.013
  29. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. 1998 Jan 15; 81(2):247-50.
    View in: PubMed
    Score: 0.013
  30. Kalscheur MM, Saxon LA, Lee BK, Steinberg JS, Mei C, Buhr KA, DeMets DL, Bristow MR, Singh SN. Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial. Heart Rhythm. 2017 06; 14(6):858-865.
    View in: PubMed
    Score: 0.012
  31. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995 May; 25(6):1225-31.
    View in: PubMed
    Score: 0.011
  32. Feldman AM, She L, McNamara DM, Mann DL, Bristow MR, Maisel AS, Wagner DR, Andersson B, Chiariello L, Hayward CS, Hendry P, Parker JD, Racine N, Selzman CH, Senni M, Stepinska J, Zembala M, Rouleau J, Velazquez EJ, Lee KL. Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials. Cardiology. 2015; 130(2):69-81.
    View in: PubMed
    Score: 0.011
  33. Bristow MR. Use of oral enoximone in pharmacologic bridging to cardiac transplantation. Z Kardiol. 1994; 83 Suppl 2:15-9.
    View in: PubMed
    Score: 0.010
  34. Feldman AM, Mann DL, She L, Bristow MR, Maisel AS, McNamara DM, Walsh R, Lee DL, Wos S, Lang I, Wells G, Drazner MH, Schmedtje JF, Pauly DF, Sueta CA, Di Maio M, Kron IL, Velazquez EJ, Lee KL. Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials. Circ Heart Fail. 2013 May; 6(3):461-72.
    View in: PubMed
    Score: 0.010
  35. Kao DP, Wagner BD, Robertson AD, Bristow MR, Lowes BD. A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PLoS One. 2012; 7(11):e48184.
    View in: PubMed
    Score: 0.009
  36. Carson P, Fiuzat M, O'Connor C, Anand I, Plehn J, Lindenfeld JA, Silver M, White M, Miller A, Davis G, Robertson AD, Bristow M, Gottlieb S. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (?-Blocker Evaluation of Survival Trial [BEST]). Am Heart J. 2010 Oct; 160(4):649-54.
    View in: PubMed
    Score: 0.008
  37. MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb; 15(1):5-8.
    View in: PubMed
    Score: 0.007
  38. Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J. 2007 Nov; 154(5):861-9.
    View in: PubMed
    Score: 0.006
  39. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Feldman AM, Galle E, Ecklund F. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation. 2006 Dec 19; 114(25):2766-72.
    View in: PubMed
    Score: 0.006
  40. Xu Y, Lu L, Greyson C, Rizeq M, Nunley K, Wyatt B, Bristow MR, Long CS, Schwartz GG. The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2006 May; 290(5):H1798-807.
    View in: PubMed
    Score: 0.006
  41. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005 Dec; 11(9):693-9.
    View in: PubMed
    Score: 0.006
  42. Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail. 2005 Mar; 11(2):83-6.
    View in: PubMed
    Score: 0.005
  43. Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Simon M, Robertson AD, Bristow MR, Wolfel EE. Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers. J Card Fail. 2004 Feb; 10(1):15-20.
    View in: PubMed
    Score: 0.005
  44. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003 Sep 03; 42(5):914-22.
    View in: PubMed
    Score: 0.005
  45. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003 Feb 19; 289(7):871-8.
    View in: PubMed
    Score: 0.005
  46. Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002 Oct 02; 40(7):1248-58.
    View in: PubMed
    Score: 0.005
  47. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001 May 03; 344(18):1358-65.
    View in: PubMed
    Score: 0.004
  48. Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, Abraham WT, Zisman LS. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail. 2001 Mar; 7(1):4-12.
    View in: PubMed
    Score: 0.004
  49. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999 Apr 15; 83(8):1201-5.
    View in: PubMed
    Score: 0.004
  50. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998 Mar; 4(1):37-44.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)